"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 1 | 6 |
| 1996 | 6 | 8 | 14 |
| 1997 | 2 | 5 | 7 |
| 1998 | 3 | 9 | 12 |
| 1999 | 5 | 7 | 12 |
| 2000 | 2 | 6 | 8 |
| 2001 | 5 | 7 | 12 |
| 2002 | 5 | 14 | 19 |
| 2003 | 6 | 9 | 15 |
| 2004 | 3 | 9 | 12 |
| 2005 | 6 | 10 | 16 |
| 2006 | 5 | 3 | 8 |
| 2007 | 1 | 6 | 7 |
| 2008 | 6 | 12 | 18 |
| 2009 | 5 | 9 | 14 |
| 2010 | 2 | 7 | 9 |
| 2011 | 6 | 12 | 18 |
| 2012 | 10 | 12 | 22 |
| 2013 | 14 | 7 | 21 |
| 2014 | 13 | 12 | 25 |
| 2015 | 21 | 11 | 32 |
| 2016 | 12 | 17 | 29 |
| 2017 | 13 | 14 | 27 |
| 2018 | 19 | 13 | 32 |
| 2019 | 13 | 11 | 24 |
| 2020 | 24 | 16 | 40 |
| 2021 | 25 | 31 | 56 |
| 2022 | 4 | 52 | 56 |
| 2023 | 5 | 43 | 48 |
| 2024 | 26 | 13 | 39 |
| 2025 | 10 | 7 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
-
Circulating Epstein-Barr Virus Antibody Levels as a Biomarker of Socioecological Adversity in Amazonian Ecuador. Am J Hum Biol. 2025 May; 37(5):e70063.
-
Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1). J Med Virol. 2025 May; 97(5):e70349.
-
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood Adv. 2025 Apr 08; 9(7):1658-1669.
-
Functional and antigenic landscape of the Nipah virus receptor-binding protein. Cell. 2025 May 01; 188(9):2480-2494.e22.
-
Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening. Cancer Biomark. 2025 Jan; 42(1):18758592241313323.
-
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone? or Flublok?) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45?years of age. Vaccine. 2025 Apr 30; 54:126991.
-
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019. J Infect Dis. 2025 Mar 17; 231(3):677-683.
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
-
Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection. mBio. 2025 Mar 12; 16(3):e0203024.